Clinical trial
Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid…
NCT00004863 · Montefiore Medical Center, Other · Completed
Key facts
| NCT number | NCT00004863 |
|---|---|
| Title | Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors |
| Official title | A Phase I Open-Label Safety Study of Escalating Doses of Taxol in Combination With Escalating Doses of GEM231 in Patients With Refractory Solid Tumors |
| Lead sponsor | Montefiore Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | GEM 231, paclitaxel |
| Enrollment | 18 |
| Start date | Jul 1, 1999 |
| Primary completion | Aug 1, 2001 |
| Completion | Aug 1, 2001 |
| First posted | Mar 15, 2004 |
| Last update posted | Sep 10, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: